Lupin's Q4 net profit up nearly 48%, stock up 1.42%

Pharmaceutical firm Lupin reported nearly 48% rise in the net profit for the fourth quarter (Q4) ended March 31 on the back of strong growth in the US, India and Japan market.

The company's net profit during the quarter was up by 47.55% to Rs 8,071 million as against Rs 5,470 million in the same period of the previous fiscal, Lupin said in a filing to the Bombay Stock Exchange (BSE) on Thursday.

Lupin's net sales for the fourth quarter (Q4) grew by 33.96% to Rs 40,913 million as compared to Rs 30,540 million in the year-ago period.

The company's EBITDA during the quarter was up by 72.7% to Rs 13,928 million as against Rs 8,066 million in the corresponding period of previous fiscal.

"We have had a stellar quarter driven by robust growth in all key markets, be it the US, India or Japan. Record approval and significant launches have enabled us to deliver the company's best results yet and we are back on the growth path," Nilesh Gupta, Managing Director, Lupin said in a statement.

We continue to ramp up our investments in research and are focused on building pipelines in niche high-value areas such as inhalation, biosimilars, and complex injectables. On the backdrop of our continued delivery on oral solids, this will drive our future growth globally, Gupta added.

At 15:21 hours, the shares of Lupin were trading up 1.42% or Rs 23.10 at Rs 1,655.55 per scrip on the BSE.